“Biologic Therapies Transforming the Treatment Landscape ”
- One prominent trend in the Persistent Corneal Epithelial Defects treatment market is the is the increasing adoption of biologic therapies such as recombinant growth factors, blood-derived eye drops, and amniotic membrane products for PCED management
- These novel therapies offer targeted healing by modulating epithelial regeneration, reducing inflammation, and enhancing tissue repair
For instance,
- For instance, growth factor-based formulations have shown faster re-epithelialization in clinical settings, improving visual outcomes in patients with neurotrophic keratitis
This trend is transforming the landscape of Persistent Corneal Epithelial Defects treatments, as the incorporation of regenerative medicine is reshaping ocular surface disease care and encouraging pipeline development of next-gen biologics
